SCHEMBL12615447

SCHEMBL12615447

Cc1ccc(S(=O)(=O)n2cc(I)c3cc(-c4nnc(NC(C)(C)C)o4)ccc32)cc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 9/20 0.64
▸ PIM2 Q9P1W9 9/20 0.64
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.36
▸ UBE2N P61088 1/20 0.36
▸ MAOA P21397 1/20 0.35
▸ MAOB P27338 1/20 0.35
▸ TP53 P04637 3/20 0.35
▸ MAPT P10636 2/20 0.35
▸ HTR6 P50406 3/20 0.35
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12616200 0.89 PIM1 (0.53) PIM1PIM2L3MBTL1KDM4EUBE2N
SCHEMBL12615793 0.89 PIM1 (0.51) PIM1PIM2L3MBTL1KDM4EUBE2N
SCHEMBL12616625 0.87 PIM1 (0.49) PIM1PIM2L3MBTL1KDM4EUBE2N
SCHEMBL12615474 0.85 PIM1 (0.51) PIM1PIM2L3MBTL1KDM4EUBE2N
SCHEMBL12615444 0.85 PIM1 (0.48) PIM1PIM2L3MBTL1KDM4EUBE2N
SCHEMBL12615435 0.85 PIM1 (0.46) PIM1PIM2L3MBTL1KDM4EUBE2N
SCHEMBL12615361 0.83 PIM1 (0.58) PIM1PIM2L3MBTL1KDM4EUBE2N
SCHEMBL15854693 0.82 PIM1 (0.46) PIM1PIM2L3MBTL1KDM4EUBE2N
SCHEMBL12615524 0.80 PIM1 (0.51) PIM1PIM2KDM4ETP53MAPT
SCHEMBL12614928 0.80 MAPT (0.55) PIM1PIM2L3MBTL1KDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9321756-B2 Azole compounds as PIM inhibitors AMGEN INC. (US) 2016-04-26 — — US disclosed
US-9321756-B2 Azole compounds as PIM inhibitors AMGEN INC. (US) 2016-04-26 — — US disclosed
US-9321756-B2 Azole compounds as PIM inhibitors AMGEN INC. (US) 2016-04-26 — — US disclosed
US-20140187553-A1 Azole Compounds as PIM Inhibitors AMGEM INC. (US) 2014-07-03 — — US disclosed
US-20140187553-A1 Azole Compounds as PIM Inhibitors AMGEM INC. (US) 2014-07-03 — — US disclosed
US-20140187553-A1 Azole Compounds as PIM Inhibitors AMGEM INC. (US) 2014-07-03 — — US disclosed
EP-2688886-A1 AZOLE COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2014-01-29 — — EP disclosed
WO-2012129338-A1 AZOLE COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-09-27 — — WO disclosed
WO-2012129338-A1 AZOLE COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-09-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140187553-A1 Azole Compounds as PIM Inhibitors PIM1, PIM3, PIM2 PIM1 1/4885PIM2 3/4885L3MBTL1 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback